cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Murdani Abdullah
Contact Email
ina.jghe@gmail.com
Phone
+6285891498517
Journal Mail Official
ina.jghe@gmail.com
Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Published by The Indonesian Society for Digestive Endoscopy
ISSN : 14114801     EISSN : 23028181     DOI : -
Core Subject : Health,
Medicine & Pharmacology
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.
Arjuna Subject : Kedokteran - Ilmu Pencernaan
Articles 7 Documents
 1 
Search results for , issue "VOLUME 3, NUMBER 3, December 2002" : 7 Documents clear
The Diagnostic and Management of Drug Induced Esophagitis Alkindi Bahar; Ari Fahrial Syam; Chudahman Manan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200286-90

Abstract

There are several factors that involve in drug induced esophagitis such as: drugs, esophagus, patients. The drug can cause direct effect to the esophageal mucosa. The drugs that often cause esphagitis: alendronate, tetracycline and its derivates and anti retroviral agents. Most of these drugs can cause esophageal damage due to corrosive nature of the drug. Esophageal factor that can cause the drug induced esophagitis: rheumatic heart disease, enlargement of the left atrium mass and aortal aneorysma. These conditions will disturb drug passage and prolongs drug contact with esophageal mucosa. The patients factor that influences this problem is the patients position when taking the drug, the patients age, the amount of water taken along with the drug, the time when drug was taken, and the amount of saliva. Endoscopy is a good procedure to evaluate the esophageal mucosa and establishing differential diagnosis through direct inspection, biopsy. In the management of esophagitis, PPIs are currently the most effectiveness agents available for treating esophagitis. Esomeprazole, an optical isomer of omeprazole is the first PPI to show greater efficacy than other PPI is in esophagitis healing.   Keywords: Esophagitis, drug induced, proton pump inhibitor.
The Efficacy of Trimethoprim-sulfamethoxazole Compared to Ciprofloxacin in The Treatment of Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites Syadra Bardiman Rasyad; Ahmar Kurniadi; Fuad Bakry Fauzi
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200276-81

Abstract

Background: The incidence of spontaneous bacterial peritonitis (SBP) is 7 to 23%, and the associated mortality rate is 25 to 40% (Rimola 1992). The aim of this study was to evaluate the efficacy of trimethoprim-sulfamethoxazole compared to ciprofloxacin in the treatment of SBP in cirrhotic patients with ascites. Materials and Method: This prospective randomized double blind study included 43 cirrhotic patients with ascites (25 males, 18 females, ages 23-75 years, one female patient died prior to laboratory evaluation) enrolled between May 1999 and June 2000, at the Department of Internal Medicine of Mohammad Hoesin General Hospital /the Medical Faculty of Sriwijaya University of Palembang, South Sumatera. Twenty-three patients (53.4%) with SBP were eligible for the study, all were randomized. Patients were divided into 2 groups (13 in group I, and 10 in group II), those receiving trimethoprim- sulfamethoxazole 960 mg once daily for 10 days and those receiving ciprofloxacin 1000 mg once daily for 10 days. Statistically, there was no significant difference in the characteristics of the 2 groups.  Results: The incidence of SBP in our study was 53.4% (23 patients out of 43 cirrhotic patients with ascites). The Results of the study demonstrate that trimethoprim-sulfamethoxazole and ciprofloxacin are both effective (91.6% and 90%) in the treatment of SBP. There was a significant decrease in ascitic fluid PMN count after 10 days treatment with both of the drugs (p=0.001 and p=0.000). There was no statistically significant difference (t-test) between the two groups in decreasing the ascitic fluid PMN count after the treatment (p=0.664). Conclusion: Trimethoprim-sulfamethoxazole and ciprofloxacin has similar efficacy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients with ascites.    Keyword: Trimethoprim-sulfamethoxazole, ciprofloxacin, spontaneous bacterial peritonitis.
Early Gastric Cancer Gontar A. Siregar
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200291-96

Abstract

Early Gastric Cancer (EGC) is a carcinoma limited to the gastric mucosa or submucosa without the involvement of any lymph node. In Indonesia, the prevalence of EGC in 1980 was 2.2% and 1.7% for Jakarta and Medan, respectively. From 1980-1987 in Surabaya, the prevalence was 9.1% from all gastric cancers. Gastric mucosal abnormalities include atrophic gastritis, which is frequently accompanied by achlorhidria or hipochlorhidria and pernicious anemia, and the presence of an ulcer or polyp were believed to be precarcinogenic factors. Environmental factors, life style, age, sex, genetic factors, race, as well as dietary factors, especially intake of foods containing N-nitrosa (N-nitrosa compound) might play a role as risk factors for EGC. H.pylori infection also causes an increased risk for EGC. The diagnosis of EGC is based on physical examination, occult blood in stool sample, cytology, double contrast roentgenologic examination, gastroscopy, gastrobiopsy, and radioactive phosphor. There are no tumor markers specific for EGC. Histologically, EGC is classified into intestinal and diffuse infiltrative EGC. In 1962, the Japanese Research Society for Gastric Cancer made a classification for EGC based on  gastroscopy, fluoroscopy, histopathology and microscopic examinations. In Japan, detection for EGC was performed by spraying the gastric mucosa with methylen blue during endoscopy, which will stain intestinal mucosa and spare normal mucosa. Early detection of EGC in Japan was performed through mass screening of people ages 40-50 years with recent dyspepsia, by means of endoscopy, biopsy, and upper GI tract radiological examinations. Endoscopic Ultrasonography (EUS) is the most accurate tool to determine EGC staging, particularly those with non-ulcerative lessions. The choices of treatment for EGC are surgical therapy or Endoscopic Mucosal Resection (EMR). EMR is a localized therapy, and it is indicated for EGC without metastases, for patients unwilling to undergo operation, or for those who are bad candidates for operation. The prognosis for EGC does not depend upon microscopic classification, but mostly on the depth of gastric mucosal invasion, spread to regional lymph nodes, and the presence of distant metastases. By establishing the diagnosis of EGC, the prognosis is usually better, for the treatment can be given at an earlier stage.   Key words: Early gastric cancer, diagnosis, treatment
Treatment of Chronic Hepatitis C with High Dose Interferon Therapy Experience from Pertamina Central Hospital Jakarta Waldemar Simanjuntak
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200282-85

Abstract

Background: Until several years ago, interferon alfa was the only drug with proven benefit for the treatment of chronic Hepatitis C. Several therapy categories such as fixed-dose regimens, induction-dose regimens and escalation-dose regimens are already known. With standard dose interferon therapy of 3 MU, TIW for 6 months, a sustained response rate can ve achieved in only 10-20% of patients. This study reports the Results of treatment of chronic Hepatitis C with high dose interferon therapy of 6 MU, TIW for 6 months. Methods: From February 1996 to February 1998, 15 patients with Hepatitis C were treated with interferon alfa-2b 6 MU, TIW for 6 months. Ultrasound-guided liver-biopsy was performed using the Menghini-Technique (Hepafix). Virological and biochemical responses were assessed at the end of the treatment period at week 24 and at the end of follow-up period at week 48 and up to 2 years later. Virological and biochemical sustained responses were defined as the absence of HCV-RNA, and SGPT concentration within the normal range at both weeks 24 and 48. Histological response was assessed after the end of treatment. Side-effects were observed and noted. Results: Ten out of 15 patients (66.7%) were HCV-RNA negative and 11 out of 15 patients (73.3%) demonstrated ALT within the normal range at week 24. At the end of the follow-up, from week 48 until 2 years later, HCV-RNA negative and normal ALT were found in 6 patients (40%). Histological improvement was found in 4 out of 6 patients. Fever was the most common side-effect and was found in 13 patients, while fatigue was found in 12 patients, myalgia in 11, headache in 10, and anorexia in 11 patients. Conclusion: High dose interferon alfa-2b therapy for the treatment of chronic Hepatitis C can improve the rate of sustained response, but is associated with more side-effects.   Key Words: Chronic hepatitis C, Interferon.
Early Acute Liver Failure In Severe Acute Hepatitis B Gontar Alamsyah Siregar
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200297-98

Abstract

Early acute liver failure is defined by the presence of a drop below 50% of the normal prothrombine ratio, jaundice, and clotting factors of less than 50% in any patient with acute liver disease. Clinical features and laboratory manifestations of viral hepatitis range from unapparent disease, asymptomatic infection, to culminant disease, which has the highest mortality rate of up to over 80 %. We report a case of a 22-year old man who was treated in a private hospital with early acute liver failure caused by hepatitis B infection. The diagnosis was based on clinical symptoms and laboratory test Results such as jaundice, hepatomegaly, ascites, 34% prothrombine ratio, elongated prothrombine time (37,1 seconds), hypoalbuminemia (1,9 g/dL), hyperbillirubinemia (total billirubin 26,35 mg/dL, direct billirubin 16,66 mg/dL, HbsAg (+), IgM anti- HBc (+), IgM anti HAV (-), and anti HCV (-). The patient suffered from jaundice for 6 weeks and on the third week, he suffered from ascites. He had improved clinical condition and laboratory test results with conservative therapy after the seventh week. At the end of the tenth week, the patient’s clinical condition and laboratory test results had reached normal, with HBsAg (-) and HBsAb (+). Whether or not interferon should have been given to this patient is still arguable.   Key words: Early acute liver failure, Severe acute hepatitis B
Lower Gastrointestinal Bleeding due to Multiple Polyps in Ileum Ivo Novita Sah Bandar; Ari Fahrial Syam; Chudahman Manan; Marcellus Simadibrata; Murdani Abdullah
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200299-101

Abstract

The causes of lower gastrointestinal bleeding (hematochezia) are amyloidosis, anal fissure, angiodysplastic lesions, coagulation disorder, colitis, colon cancer, colorectal polyps, Crohn’s disease, diverticulitis, haemorrhoids, etc. This was a case of lower gastrointestinal bleeding due to colonic inflammatoric polyp. This inflammatoric polyps were caused by infection/inflammation and improved after antibiotic and NSAID therapy. Key Words : Colonic inflammatoric polyp, hematochezia.
Nitric Oxide and von Willebrand Factor Levels as Markers of Endothelial Dysfunction in Liver Cirrhosis Juwita Sembiring; Suara Ginting; Abiran Nababan; Lukman Hakim Zain; Pengarapen Tarigan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200269-75

Abstract

Introduction: A number of investigators have shown that endothelial dysfunction in liver cirrhosis can be indicated by increased levels of nitric oxide (NO) and von Willebrand factor (vWF). The cause of this increase is still unclear. It is believe to be correlated with hyperdinamic circulation and endotoxemia, which are common in liver cirrhosis. The Aim of This Study: To compare the levels of NO and vWF in liver cirrhosis patients with those in healthy control subjects, and to investigate whether there is a correlation between levels of NO and vWF with the severity of the disease according to the Child Pugh Criteria Material and Method: This study was conducted from February until June 2001 in 35 liver cirrhosis patients at Dr. Pirngadi and H. Adam Malik Hospital and some private hospitals in Medan. The mean age of patients with liver cirrhosis was 54  + 12.26 years, the youngest being 31 years and the oldest 75 years, and 20 healthy controls while the mean age of the control subject was 55.20 + 13.04 years, the youngest being 31 years and the oldest 76 years. Based on Child Pugh criteria, 9 were classified as Child Pugh class A, 13 in class B, 13 in class C. The criteria for liver cirrhosis were based on clinical examination, laboratory findings and liver ultrasound examination. Cirrhotic patients with hypercolestrolemia, hypertension, heart failure, myocardial infraction, renal failure diabetes, COPD were those on drugs, such as antibiotics and branchodilators were excluded from the study. Result: The mean level of NO in patients with liver cirrhosis was 6.2600  + 4.4456 mM, while the mean NO level in control subjects was 3.2325  + 3.2355 mM, p0.05. The mean level of NO in Child Pugh class A patients was 6.6889  + 3.9757mM, compared to control p0.05; in Child Pugh class B the mean level was 4.8308  + 2.4642 mM compared to control p0.05. There was a significant increase in the level of NO associated with the severity of liver cirrhosis. The mean level of vWF in patients with liver cirrhosis was 399.514  + 175.313% while the mean vWF level in control subjects was 139.100 + 51.144%, p0.05. The mean level of vWF in Child Pugh class A patients was 231.778 ± 43.8576%, compared to control p0.05; in Child Pugh class B was 365.846 + 110.034%, compared to control p0.05, in Child Pugh class C was 549.308 + 164.483%, compared to control p0.05. There was significant increase in the level of vWF correlated with severity of liver cirrhosis. Conclusion: The level of NO was significant higher in liver cirrhosis patients compared to control subjects, but there was no correlation between the increase in the level of NO with the severity of the disease. The levels of vWF was significantly higher in liver cirrhosis patients compared to control, and there was a correlation between increased levels of vWF and the severity of the disease.  Key Words: Liver cirrhosis, Child Pugh criteria, nitric oxide (NO), von Willebrand Factor (vWF)

Page 1 of 1 | Total Record : 7

 1 

Filter by Year

2002 2002


Reset
Filter By Issues
All Issue Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, AGUSTUS, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue